8-K/A - Roivant Sciences Ltd. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Roivant Sciences Ltd. amended its 8-K to file Exhibit 10.1, a Settlement Agreement dated March 3, 2026, between Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd. (solely for certain purposes), and Moderna, Inc. and ModernaTX, Inc., resolving all U.S. and international patent infringement litigations over Genevant/Arbutus’ lipid nanoparticle technology used in Moderna's vaccines.

Key Takeaways

1Settlement Agreement effective March 3, 2026, resolves US Litigation (Civil Action No. 1-22-cv-00252-JDW in Delaware District Court) and Ex-US Litigation (Canada T-704-25, Japan 2025 (Wa) 70079, Switzerland O2025 002, UPC cases, EPO oppositions)

2Parties include Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd., Moderna Inc., ModernaTX Inc.

3Covers Asserted US Patents (Nos. 8,058,069; 8,492,359; 8,822,668; 9,364,435; 9,504,651; 11,141,378) and Asserted Ex-US Patents (Canada 2,721,333; Japan 5,475,753; EP 2279254; EP 4241767)

4Applies to Moderna Licensed Products: SPIKEVAX, mNEXSPIKE, mRESVIA, and other SM-102 LNP mRNA vaccines against infectious diseases

5Mutual releases of all claims related to litigations and patent infringement upon Moderna's noncontingent lump sum payment

6Preserves Moderna's right to appeal §1498 Disputed Matter regarding 493,757,200 Disputed Doses under C-100 Contract

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Amendment

Variant

8-K/A

Items Reported

1.01

. Entry into a Material Definitive Agreement The disclosure set forth in Item 1.01 of the Original 8-K is hereby incorporated by reference. As described in the

Material Agreement

Source Document

9.01

. Financial Statements and Exhibits (d) Exhibits. Exhibit No. Description of Exhibit 10.1*^ Settlement Agreement, dated March 3, 2026. 104 Cover Page Interactiv

Exhibits Only

Transaction Details

Material Agreement

Agreement: Settlement Agreement
Parties: Genevant Sciences GmbH, Arbutus Biopharma Corp., Genevant Sciences Ltd. (solely for certain purposes), Moderna, Inc., ModernaTX, Inc.

•Resolves US Litigation (Civil Action No. 1-22-cv-00252-JDW) and Ex-US Litigation including Canada Federal Court T-704-25, Japan Tokyo District Court 2025 (Wa) 70079, Switzerland O2025 002, UPC_CFI_191/2025, UPC_CFI_192/2025, EPO oppositions on EP 2279254 and 4241767
•Mutual full releases of claims related to litigations and Genevant/Arbutus Patent Rights infringement effective upon Moderna's noncontingent lump sum payment
•Stipulates to entry of judgment in US Litigation preserving Moderna's appeal on §1498 Disputed Matter for 493,757,200 Disputed Doses under C-100 Contract
•Grants Moderna license to Genevant/Arbutus Patent Rights and EPO Patent Rights for Moderna Licensed Products (SPIKEVAX, mNEXSPIKE, mRESVIA, other SM-102 LNP mRNA vaccines)

Exhibits (2)

10.1

EXHIBIT 10.1

8-K/A